Saturday, November 19, 2022

Hilton Columbus Downtown, 401 North High Street, Columbus, OH 43215

Notice: The Ohio State University is monitoring the incidence of COVID-19 in the Columbus area. At this time, there are no restrictions for Summit attendees. Any updates will be posted on this page.

Audience

  • Senior and junior faculty and fellows involved in clinical oncology research
  • Basic scientists involved in drug discovery and translational research
  • Cancer center leadership and administration
  • Industry leaders and medical science liaisons
  • Community leaders

Cost

  • Faculty, Staff, Researchers, Fellows: Free
  • Patient Advocates: Free
  • Industry (Individual): $800
  • Industry (Group) up to 10 attendees: $5,000

Vendor tables are available to industry registrants for an additional $250. If your company already registered to give a pipeline presentation (all spots are now filled), you will receive a complimentary vendor table.

Registration

Registration is closed. 

Hosted By

Thank you to The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J Solove Research Institute (OSUCCC – James), for hosting the Big Ten CRC Summit!

The OSUCCC – James is the only cancer program in the United States that features a National Cancer Institute (NCI) – designated comprehensive cancer center aligned with a nationally ranked academic medical center and a freestanding cancer hospital on the campus of one of the nation’s largest public universities. 

Questions?

Contact Sarah Schmidt at sarah.schmidt@osumc.edu.

Agenda

Saturday, November 19, 2022

All times are ET

  • 8:15 – 8:30 AM
    Meet and Greet (Breakfast Provided)
  • 8:30 – 8:45 AM
    Welcome: Raphael Pollock, MD, Director, The Ohio State University Cancer Center (OSUCCC); George Weiner, MD, Director, Holden Comprehensive Cancer Center at The University of Iowa; Howard Bailey, MD, Director, University of Wisconsin Carbone Cancer Center. 
  • 8:45 – 9:15 AM
    At the Convergence of Technology and Cancer Biology: Erik Nelson, PhD, Cancer Center at Illinois;
  • 9:15 – 9:45 AM
    Bladder Cancer Project: DUART
    Monika Joshi, MD, MRCP, Penn State Cancer Institute; Chief Scientific Officer, Big Ten CRC
  • 9:45 – 10:15 AM
    Nanoparticle-Based Immunotherapy
    Yoon Yeo, PhD; Professor, Industrial and Physical Pharmacy, Purdue University 
  • 10:15 AM
    Break
  • 10:30 – 11:30 AM
    Industry Pipeline Presentations
    Jazz Pharma; Guardant Health; Zeiss Microscopy
  • 11:30 – 12:00 PM
    Lunch
  • 12:00 – 12:45 PM
    Collaborative Panel Discussion – Clinical Cancer Research Challenges and Lessons from the Big Ten CRC Moderator: Dwight Owen, MD, MS, The Ohio State University Panelists: Angie Campbell, MS, OSU; John Hays, MD, PhD; Greg Durm, MD, Indiana; Nataliya Uboha, MD, PhD, Wisconsin.  
  • 12:45 – 1:30 PM
    Collaborative Panel Discussion – Pancreatic Cancer Future Trial Designs Across the Therapeutic Spaces: Discussion of Necessary Standard Modalities and Target Endpoints Moderator: Laith Abushahin, MBBS, Ohio State University; Akhil Chawla, MD, Northwestern (Surgical Oncology); Dayssy Diaz Pardo, MD, OSU (Radiation Oncology); Nataliya Uboha, MD, PhD, Wisconsin (Department of Medicine) 
  • 1:30 – 2:15 PM
    Population Science and Cancer Prevention Panel Discussion: 
    Moderator: Electra Paskett, PhD, The Ohio State University and Sharon Manne, PhD, Rutgers University;
    Panelists: Electra Paskett, PhD, OSU, “Mission and Progress for the Big Ten Population Science Working Group”; 
    Sharon Manne, PhD, Rutgers, “Approaches to Assessing and Addressing Unmet Catchment Area Needs Across the Big Ten Cancer Centers”;
    Darren Mays, MPH, PhD, OSU “Awareness of Alcohol Use As A Behavioral Risk Factor for Breast Cancer in Young Women: Intervention Implications”
  • 2:15 – 3:15 PM
    Comparative Oncology Panel Discussion
    Panelists: William Kisseberth, DVM, MS, PhD, DACVIM,” Comparative Oncology Introduction”;  OSU;Tim Fan, PhD, DVM, Illinois, “Development of PAC-1 for Pet Dogs and Humans with Malignant Intracranial Tumors”;   David Vail, DVM, MS, DACVIM, Wisconsin, “Targeted Radionuclide Therapy and the Interface between Radiation and Immunotherapy” 

 

Registration Form